Breaking Through the Treatment Desert of CAR-T Cell Therapy for Malignant Mesothelioma
Malignant mesothelioma is a rare and aggressive cancer caused by asbestos exposure. Treatment options are limited. This is especially true for elderly patients. They may struggle with conventional therapies due to their age and other health problems. Chimeric antigen receptor (CAR)-T cell therapy has shown promise in treating various cancers, including malignant mesothelioma. CAR-T cell therapy works by targeting tumor-specific antigens. However, the journey has been fraught with challenges, particularly concerning the mesothelin (MSLN) antigen. A new article explores the latest advancements in CAR-T cell therapy for malignant mesothelioma and what the future holds for patients. The Challenge of Mesothelin-Targeted CAR-T Cells MSLN is a popular tumor antigen for mesothelioma. Initial trials with MSLN-targeted CAR-T cells showed low effectiveness but…